Mgr. Jiřina Kovářová, Ph.D.

Associate scientist

Publication

Nanomedicine: Nanotechnology; Biology and Medicine. 2024; 56(February 2024); 102730

Chemosensitization of tumors via simultaneous delivery of STAT3 inhibitor and doxorubicin through HPMA copolymer-based nanotherapeutics with pH-sensitive activation.

eLife. 2023; 12(Jan 27); e79342

Regulatory T cells suppress the formation of potent KLRK1 and IL- 7R expressing effector CD8 T cells by limiting IL-2

Nanomedicine: Nanotechnology; Biology and Medicine. 2022; 44(August); 102578

Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines

Pharmaceutics. 2022; 14(6); 1201

HPMA copolymer mebendazole conjugate allows systemic administration and possesses antitumour activity in vivo

Biomacromolecules. 2022; 23(6); 2522-2535

Simultaneous delivery of doxorubicin and protease inhibitor derivative to solid tumors via star-shaped polymer nanomedicines overcomes P-gp- and STAT3-mediated chemoresistance

eLife. 2021; 10(DEC 21 2021); e62432

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-gamma production by CD25(+)Foxp3(-) T cells

Journal of Controlled Release. 2021; 332(APR 10 2021); 563-580

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling

Elife . 2021 Dec 21;10:e62432

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-γ production by CD25+Foxp3- T cells